At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. To achieve this, we pursue an integrated access strategy that focuses our work on improving access to medicines, access to medical information and access to medical capacity building. This includes efforts to provide and support appropriate training for healthcare professionals. In 2015, our products reached an estimated 500 million patients and our aspiration is to reach one billion people.
At least 400 million people worldwide cannot access essential health services and more than 2 billion cannot afford to buy the medicines they need.
Sandoz emphasizes and maintains a strong working partnership with the NHS. Our purpose is to help the NHS treat more patients and thereby ensure that medical access is provided for a wider group of individuals. The broad portfolio that Sandoz offers covers a range of high quality off-patent medicines including biosimilars and harder to make generics.
In addition to the leading global rankings in biosimilars and generic antibiotics, dermatology and transplantation medicines, Sandoz has a very strong presence in areas ranging from generic cardiovascular to oncology. Our broad portfolio is backed by a range of state-of-the-art technologies, formulations and devices.
We have strong scientific roots that have driven many medical innovations, from the first oral penicillin in 1951 to the first biosimilars in Europe and the US. We go beyond providing standard products and add value to the healthcare system through a range of support services and value-added medicines including combination formulations.